Rheumatoid Arthritis Clinical Trial
Official title:
Prospective Single-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy ASR™ Hip in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty
Verified date | June 2017 |
Source | DePuy International |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to monitor the performance and determine the metal ion release
of the DePuy ASR™ System in the treatment of patients with hip joint disease requiring hip
resurfacing surgery. Patients who enter the study will be evaluated at regular intervals
following hip surgery using patient, clinical and x-ray assessments. A subset of patients
will also have blood samples taken at regular intervals to allow the metal ion levels to be
determined and undergo scans to allow the bone mineral density of the bone surrounding the
implant to be monitored.
DePuy decided to close this Study in 4Q 2009. The Study was terminated with effect from
November 2010 to allow for the completion of the 5 year follow up assessments.
Please note that subsequent to this decision DePuy voluntarily recalled the ASR products on
24 August 2010. Additional information regarding this voluntary recall and the follow-up of
patients affected by the recall can be found at the following links
http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON079157 and
http://www.depuy.com/countries_list.
Status | Terminated |
Enrollment | 50 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: i) Male or female subjects, aged between 18 and 65 years inclusive. ii) Subjects with current indications for standard MoM hip resurfacing arthroplasty suitable for cementless fixation in the acetabulum. These include pain, deformity, and loss of function, which are not responsive to medical treatment. iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained. iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. Exclusion Criteria: i) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study. ii) Subjects with proven significant osteoporosis and poor bone quality. iii) Subjects with compromised renal function. iv) Subjects with proven metal sensitivity. v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc. vi) Women who are pregnant. vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. viii) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s). ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation. x) Subjects who are currently involved in any injury litigation claims. Additional Exclusion Criteria for Subjects Undergoing Blood Analysis 1. Subjects who currently have other metallic foreign bodies including trauma products and joint arthroplasties unless known to be pure titanium, titanium alloy. 2. Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision operations |
Country | Name | City | State |
---|---|---|---|
South Africa | St Augustine's Hospital | Durban |
Lead Sponsor | Collaborator |
---|---|
DePuy International |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Kaplan-Meier survivorship at two years | 2 years | ||
Secondary | UCLA Activity Score | Annually | ||
Secondary | WOMAC Score | Annually | ||
Secondary | Activity Assessment. | Annually | ||
Secondary | Kaplan-Meier survivorship calculation | Annually | ||
Secondary | Harris Hip Score | pre-discharge, 3mths, 1yr, 2yrs, 5yrs,10yrs and 15yrs post-surgery | ||
Secondary | Radiographic analysis | pre-discharge, 3mths, 1yr, 2yrs, 5yrs,10yrs and 15yrs post-surgery | ||
Secondary | Metal ion analysis in whole blood | 3mths, 6mths, 1yr, 2yrs and 5 yrs post-surgery | ||
Secondary | Bone mineral density (DEXA) | 3mths, 1yr, 2yrs and 5 yrs post-surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |